CTOs on the Move

Carrot Fertility

www.get-carrot.com

 
Carrot is a complete global fertility solution for today`s modern employers and payers, providing flexible financial coverage and expert care navigation across the U.S. and 50+ countries. Get a quick demo and briefing about how modern companies are using Carrot to drive down healthcare costs, attract and retain top talent, and build cultures of inclusion.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Jobs

VP, Chief Information Security Officer

Carrot Fertility Remote

Funding

Carrot Fertility raised $24M on 08/18/2020

Similar Companies

HealthCare Ventures

HealthCare Ventures LLC is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lanx

Lanx is one of the largest and fastest growing private spine companies in the U.S. The Company was founded by a team of experienced medical device professionals and engineers in 2003 to improve the quality of spine care and provide surgeons with innovative products.

Vesta Healthcare

At Vesta Healthcare, we believe that improving quality of life is possible when we connect technology with clinical expertise, and caregivers and care recipients with the care team.

U M W A Health and Retirement Fund

U M W A Health and Retirement Fund is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.